INTRICON CORPORATION (NASDAQ:IIN) Files An 8-K Results of Operations and Financial Condition

Item 2.02Results of Operations and Financial
Condition.

The following information is being provided to Item 2.02. Such
information, including Exhibit 99.1 attached hereto, should not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act).

On February 16, 2017, IntriCon Corporation (the Company)
announced earnings for the quarter ended December 31, 2016. A
copy of the press release is furnished as Exhibit 99.1 and is
incorporated herein by reference.

Item 2.05Costs Associated with Exit or
Disposal Activities.

On December 30, 2016, the Board of Directors of the Company
approved the divestiture of the Companys cardiac diagnostic
monitoring business (the CDM Business) and authorized management
to begin a sale process. At the time the divestiture was approved
in principle, the impairment charges were not expected to be
material.

On January 30, 2017, the Audit Committee of the Board of
Directors, in consultation with management and in connection with
the review of the Companys financial statements for 2016,
approved an estimated non-cash charge of approximately $796,000
for impairment of fixed assets, inventory and accounts receivable
of the CDM Business. This charge has been recorded in the
Companys results from discontinued operations for the quarter
ended December 31, 2016. The change in the estimated impairment
charge was based upon a change in the purchase price that was
expected to be received from the sale of the CDM Business as a
result of negotiations with the prospective purchaser. The
disposition of the CDM Business is not expected to result in
future cash expenditures other than professional fees aggregating
less than $50,000.

On February 16, 2017, the Company informed affected employees of
the CDM Business of the disposition.

Additional losses are possible as the Company completes the
divestiture of the CDM Business.

Item 2.06Material Impairments.

The information set forth above in Item 2.05 is hereby
incorporated into Item 2.06 by reference.

Item 7.01Regulation FD Disclosure.

The following information is being provided to Item 7.01. Such
information, including Exhibit 99.1 attached hereto, should not
be deemed filed for purposes of Section 18 of the Exchange Act.

The information contained under Item 2.02 is incorporated herein
by reference.

Forward-Looking Statements

Statements made in this Current Report on Form 8-K that are not
historical facts, such as estimates of costs or charges as a
result of the disposition of the CDM Business, or that include
forward-looking terminology, such as estimated, expected and
anticipated, are forward-looking statements within the meaning of
the Securities Exchange Act of 1934, as amended. These
forward-looking statements may be affected by known and unknown
risks, uncertainties and other factors that are beyond the
Companys control, and may cause the Companys actual results,
performance or achievements to differ materially from the
results, performance and achievements expressed or implied in the
forward-looking statements. These risks, uncertainties and other
factors are detailed from time to time in the Companys filings
with the Securities and Exchange Commission, including the Annual
Report on Form 10-K for the year ended December 31, 2015. The
Company disclaims any intent or obligation to publicly update or
revise any forward-looking statements, regardless of whether new
information becomes available, future developments occur or
otherwise.

Item 9.01Financial Statements and
Exhibits.

(d)Exhibits.

About INTRICON CORPORATION (NASDAQ:IIN)

IntriCon Corporation is engaged in designing, developing, engineering, manufacturing and distributing body-worn devices. The Company operates through body-worn device segment. The Company serves the body-worn device market by designing, developing, engineering and manufacturing micro-miniature products, microelectronics, micro-mechanical assemblies, complete assemblies and software solutions, primarily for the value hearing health market, the medical bio-telemetry market and the professional audio communication market. The Company has facilities in Minnesota, California, Singapore, Indonesia, the United Kingdom and Germany, and operates through its subsidiaries. The Company’s product offering includes a hearing aid discount program for health plans. This program is available around the nation to health insurers, including employer-sponsored, individual and Medicare plans. The Company also has various international value hearing aid (VHA) initiatives.

INTRICON CORPORATION (NASDAQ:IIN) Recent Trading Information

INTRICON CORPORATION (NASDAQ:IIN) closed its last trading session up +0.05 at 7.70 with 14,767 shares trading hands.